DAVA Oncology
@DAVAOnc
DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
قد يعجبك
Announcing the 8th Summit on Genitourinary Malignancies by DAVA Oncology! Join us this November to explore the latest data and emerging strategies in bladder, kidney & prostate cancer. Keep your 👀 on our socials for a sneak peek. Check out the website! dava.link/BermudaGU25
@DAVAOnc Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI
Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! #livertwitter
Nice to see friends, mentors and industry partners to embark on more trials in PDAC. @utswcancer
Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI
Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬
Excited to have these trials available for our patients! @AdventHealthCFL @drzakoncology
ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI
Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc
Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs @sepideh_gholami #livertwitter
The very last @DAVAOnc summit on GI malignancies is underway. Congratulations to @vinaykjain17 and the DAVA team for another tour de force. Over 170 talks in 4 days. Lots of fruitful interactions and learning! #DAVAGI
The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI
Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI
EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI
CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.
At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.
Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors Moderated by: Dr. Manish Shah @WeillCornell #DAVAGI
Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI
In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI
Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI
United States الاتجاهات
- 1. D’Angelo 100K posts
- 2. Brown Sugar 9,437 posts
- 3. Black Messiah 4,025 posts
- 4. #GoodTimebro 1,429 posts
- 5. Powell 30K posts
- 6. Happy Birthday Charlie 104K posts
- 7. Voodoo 9,747 posts
- 8. How Does It Feel 5,246 posts
- 9. #BornOfStarlightHeeseung 72.8K posts
- 10. #csm217 3,329 posts
- 11. Rest in Power 10.6K posts
- 12. Alex Jones 23.6K posts
- 13. #PortfolioDay 7,193 posts
- 14. Sandy Hook 8,664 posts
- 15. Pentagon 90K posts
- 16. Neo Soul N/A
- 17. Jill Scott N/A
- 18. Osimhen 58.9K posts
- 19. #tuesdayvibe 5,820 posts
- 20. Untitled 4,353 posts
قد يعجبك
-
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Krina Patel
@DrKrinaPatel -
drjoannarhodes
@drjoannarhodes1 -
SWOG Cancer Research Network
@SWOG -
Suresh S. Ramalingam, MD, FASCO
@RamalingamMD -
Eric J. Small, MD, FASCO
@ASCOPres -
Jason Westin, MD FACP FASCO
@Lymphoma_Doc -
iwCLL
@iwCLL -
Vishal Navani, MD
@navstruck -
Julie Vose
@DrJulieVose -
Tycel Phillips
@LymphClinician -
Ticiana Batista (Leal)
@LealTiciana -
Binay Shah, MD, MHA
@binayshah -
Danilov Lab
@DanilovLab -
Andrew M. Evens, DO, MBA, MSc
@DrAEvens
Something went wrong.
Something went wrong.